Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: Correlation between drug concentration and clinical response

Alfonso M. Lostia, Lorenzo Mazzarini, Isabella Pacchiarotti, Luana Lionetto, Pietro De Rossi, Livia Sanna, Gabriele Sani, Giorgio D. Kotzalidis, Paolo Girardi, Maurizio Simmaco, Roberto Tatarelli

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The aim of this study was to assess a method able to analyze serum levels of risperidone (RIS) and its metabolite, 9-hydroxyrisperidone (9-OH-RIS), and to investigate possible relationships between changes in serum concentrations of these drugs and clinical measures, so to identify early markers of treatment response. The authors developed a sensitive and specific liquid chromatography-tandem mass spectrometry method to measure RIS and its metabolite in serum. Fifteen RIS-naive patients were admitted to an acute psychiatric care unit and treated with 4-6 mg/d oral RIS. At days 7 and 21 of hospital stay, serum levels were measured; clinical scales and serum prolactin were assessed. RIS and its metabolite were analyzed by a Q-Trap 2000 triple quadrupole/ion trap mass spectrometer in the multiple reaction-monitoring mode. Chromatographic separation was accomplished using a cyano column with an analytical run of 9 minutes. The calibration curve exhibited consistent linearity and reproducibility in the range 0-100 ng/mL for both analytes. Lower limit of quantification was 0.2 ng/mL; limit of detection, for a signal to noise ratio of 3, was 0.05 ng/mL for both analytes. Serum RIS and 9-OH-RIS levels increased at day 7, reaching a steady state, and remaining constant up to day 21. Scores on psychopathology rating scales decreased; serum prolactin and neurological rating scale for extrapyramidal effects rose at day 7 and remained stable thereafter. No correlation was found between serum concentration values, including sum and ratio of RIS and 9-OH-RIS, and any of the other clinical values (serum prolactin and clinical scales). These data indicate that clinical changes are related to the achievement of steady state levels of RIS and its metabolite and are maintained, but not continued, with continued RIS treatment. Therapeutic drug monitoring of RIS and its metabolites is not recommended as a routine procedure in patients with psychotic disorders.

Original languageEnglish
Pages (from-to)475-481
Number of pages7
JournalTherapeutic Drug Monitoring
Volume31
Issue number4
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Risperidone
Serum
Pharmaceutical Preparations
Prolactin
Paliperidone Palmitate
Drug Monitoring
Signal-To-Noise Ratio
Tandem Mass Spectrometry
Psychopathology
Liquid Chromatography
Psychotic Disorders
Calibration
Psychiatry
Limit of Detection
Length of Stay

Keywords

  • 9-hydroxyrisperidone
  • LC-MS/MS
  • Prolactin
  • Risperidone
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone : Correlation between drug concentration and clinical response. / Lostia, Alfonso M.; Mazzarini, Lorenzo; Pacchiarotti, Isabella; Lionetto, Luana; Rossi, Pietro De; Sanna, Livia; Sani, Gabriele; Kotzalidis, Giorgio D.; Girardi, Paolo; Simmaco, Maurizio; Tatarelli, Roberto.

In: Therapeutic Drug Monitoring, Vol. 31, No. 4, 08.2009, p. 475-481.

Research output: Contribution to journalArticle

Lostia, AM, Mazzarini, L, Pacchiarotti, I, Lionetto, L, Rossi, PD, Sanna, L, Sani, G, Kotzalidis, GD, Girardi, P, Simmaco, M & Tatarelli, R 2009, 'Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: Correlation between drug concentration and clinical response', Therapeutic Drug Monitoring, vol. 31, no. 4, pp. 475-481. https://doi.org/10.1097/FTD.0b013e3181aa4780
Lostia, Alfonso M. ; Mazzarini, Lorenzo ; Pacchiarotti, Isabella ; Lionetto, Luana ; Rossi, Pietro De ; Sanna, Livia ; Sani, Gabriele ; Kotzalidis, Giorgio D. ; Girardi, Paolo ; Simmaco, Maurizio ; Tatarelli, Roberto. / Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone : Correlation between drug concentration and clinical response. In: Therapeutic Drug Monitoring. 2009 ; Vol. 31, No. 4. pp. 475-481.
@article{4752a483f6444a12a94b6ad305996cbe,
title = "Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: Correlation between drug concentration and clinical response",
abstract = "The aim of this study was to assess a method able to analyze serum levels of risperidone (RIS) and its metabolite, 9-hydroxyrisperidone (9-OH-RIS), and to investigate possible relationships between changes in serum concentrations of these drugs and clinical measures, so to identify early markers of treatment response. The authors developed a sensitive and specific liquid chromatography-tandem mass spectrometry method to measure RIS and its metabolite in serum. Fifteen RIS-naive patients were admitted to an acute psychiatric care unit and treated with 4-6 mg/d oral RIS. At days 7 and 21 of hospital stay, serum levels were measured; clinical scales and serum prolactin were assessed. RIS and its metabolite were analyzed by a Q-Trap 2000 triple quadrupole/ion trap mass spectrometer in the multiple reaction-monitoring mode. Chromatographic separation was accomplished using a cyano column with an analytical run of 9 minutes. The calibration curve exhibited consistent linearity and reproducibility in the range 0-100 ng/mL for both analytes. Lower limit of quantification was 0.2 ng/mL; limit of detection, for a signal to noise ratio of 3, was 0.05 ng/mL for both analytes. Serum RIS and 9-OH-RIS levels increased at day 7, reaching a steady state, and remaining constant up to day 21. Scores on psychopathology rating scales decreased; serum prolactin and neurological rating scale for extrapyramidal effects rose at day 7 and remained stable thereafter. No correlation was found between serum concentration values, including sum and ratio of RIS and 9-OH-RIS, and any of the other clinical values (serum prolactin and clinical scales). These data indicate that clinical changes are related to the achievement of steady state levels of RIS and its metabolite and are maintained, but not continued, with continued RIS treatment. Therapeutic drug monitoring of RIS and its metabolites is not recommended as a routine procedure in patients with psychotic disorders.",
keywords = "9-hydroxyrisperidone, LC-MS/MS, Prolactin, Risperidone, Therapeutic drug monitoring",
author = "Lostia, {Alfonso M.} and Lorenzo Mazzarini and Isabella Pacchiarotti and Luana Lionetto and Rossi, {Pietro De} and Livia Sanna and Gabriele Sani and Kotzalidis, {Giorgio D.} and Paolo Girardi and Maurizio Simmaco and Roberto Tatarelli",
year = "2009",
month = "8",
doi = "10.1097/FTD.0b013e3181aa4780",
language = "English",
volume = "31",
pages = "475--481",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone

T2 - Correlation between drug concentration and clinical response

AU - Lostia, Alfonso M.

AU - Mazzarini, Lorenzo

AU - Pacchiarotti, Isabella

AU - Lionetto, Luana

AU - Rossi, Pietro De

AU - Sanna, Livia

AU - Sani, Gabriele

AU - Kotzalidis, Giorgio D.

AU - Girardi, Paolo

AU - Simmaco, Maurizio

AU - Tatarelli, Roberto

PY - 2009/8

Y1 - 2009/8

N2 - The aim of this study was to assess a method able to analyze serum levels of risperidone (RIS) and its metabolite, 9-hydroxyrisperidone (9-OH-RIS), and to investigate possible relationships between changes in serum concentrations of these drugs and clinical measures, so to identify early markers of treatment response. The authors developed a sensitive and specific liquid chromatography-tandem mass spectrometry method to measure RIS and its metabolite in serum. Fifteen RIS-naive patients were admitted to an acute psychiatric care unit and treated with 4-6 mg/d oral RIS. At days 7 and 21 of hospital stay, serum levels were measured; clinical scales and serum prolactin were assessed. RIS and its metabolite were analyzed by a Q-Trap 2000 triple quadrupole/ion trap mass spectrometer in the multiple reaction-monitoring mode. Chromatographic separation was accomplished using a cyano column with an analytical run of 9 minutes. The calibration curve exhibited consistent linearity and reproducibility in the range 0-100 ng/mL for both analytes. Lower limit of quantification was 0.2 ng/mL; limit of detection, for a signal to noise ratio of 3, was 0.05 ng/mL for both analytes. Serum RIS and 9-OH-RIS levels increased at day 7, reaching a steady state, and remaining constant up to day 21. Scores on psychopathology rating scales decreased; serum prolactin and neurological rating scale for extrapyramidal effects rose at day 7 and remained stable thereafter. No correlation was found between serum concentration values, including sum and ratio of RIS and 9-OH-RIS, and any of the other clinical values (serum prolactin and clinical scales). These data indicate that clinical changes are related to the achievement of steady state levels of RIS and its metabolite and are maintained, but not continued, with continued RIS treatment. Therapeutic drug monitoring of RIS and its metabolites is not recommended as a routine procedure in patients with psychotic disorders.

AB - The aim of this study was to assess a method able to analyze serum levels of risperidone (RIS) and its metabolite, 9-hydroxyrisperidone (9-OH-RIS), and to investigate possible relationships between changes in serum concentrations of these drugs and clinical measures, so to identify early markers of treatment response. The authors developed a sensitive and specific liquid chromatography-tandem mass spectrometry method to measure RIS and its metabolite in serum. Fifteen RIS-naive patients were admitted to an acute psychiatric care unit and treated with 4-6 mg/d oral RIS. At days 7 and 21 of hospital stay, serum levels were measured; clinical scales and serum prolactin were assessed. RIS and its metabolite were analyzed by a Q-Trap 2000 triple quadrupole/ion trap mass spectrometer in the multiple reaction-monitoring mode. Chromatographic separation was accomplished using a cyano column with an analytical run of 9 minutes. The calibration curve exhibited consistent linearity and reproducibility in the range 0-100 ng/mL for both analytes. Lower limit of quantification was 0.2 ng/mL; limit of detection, for a signal to noise ratio of 3, was 0.05 ng/mL for both analytes. Serum RIS and 9-OH-RIS levels increased at day 7, reaching a steady state, and remaining constant up to day 21. Scores on psychopathology rating scales decreased; serum prolactin and neurological rating scale for extrapyramidal effects rose at day 7 and remained stable thereafter. No correlation was found between serum concentration values, including sum and ratio of RIS and 9-OH-RIS, and any of the other clinical values (serum prolactin and clinical scales). These data indicate that clinical changes are related to the achievement of steady state levels of RIS and its metabolite and are maintained, but not continued, with continued RIS treatment. Therapeutic drug monitoring of RIS and its metabolites is not recommended as a routine procedure in patients with psychotic disorders.

KW - 9-hydroxyrisperidone

KW - LC-MS/MS

KW - Prolactin

KW - Risperidone

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=68449091370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449091370&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e3181aa4780

DO - 10.1097/FTD.0b013e3181aa4780

M3 - Article

C2 - 19531984

AN - SCOPUS:68449091370

VL - 31

SP - 475

EP - 481

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 4

ER -